[Epoetin-induced pure red-cell aplasia]

Area of Science:

• Hematology
• Nephrology
• Immunology

Background:

• Erythropoiesis-stimulating agents (ESAs) like epoetin are used to treat anemia in patients with renal insufficiency.
• Anemia management in chronic kidney disease often involves ESAs to stimulate red blood cell production.

Observation:

• Three patients treated with epoetin for anemia due to renal insufficiency developed resistance to the drug.
• Despite dose increases, hemoglobin levels decreased, leading to transfusion dependence.
• One patient developed antibodies against epoetin, resulting in epoetin-induced pure red-cell aplasia.

Findings:

• The younger male patient's anemia resolved after discontinuing epoetin, demonstrating antibodies against the drug, and initiating immunosuppressive therapy post-kidney transplantation.
• The incidence of epoetin resistance due to anti-epoetin antibodies has been rising since 1998.
• Two patients experienced fatal outcomes (peritonitis and septic shock) related to their anemia and ESA resistance.

Implications:

• Epoetin-induced pure red-cell aplasia is an emerging complication that must be considered in patients with unexplained transfusion-dependent anemia during ESA therapy.
• This condition necessitates diagnostic evaluation for anti-drug antibodies and may require alternative treatments, including immunosuppression.
• The findings highlight the importance of monitoring for ESA resistance and potential immunogenicity in patients with chronic kidney disease anemia.